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-“…For this reason I will tell you my name, which is Nefernefernefer. My eyes are as 
green as Nile water in the heat of summer. I am judged so beautiful that no one, 
after having said my name three times, can avoid forgetting me.” 
Sinuhe, The Egyptian, by Mika Waltari  (1945) 
 
In the immortal classical novel by Finnish writer Mika Waltari (1908-1979) (Figure), 
Nefer, a beautiful and cunning Egyptian courtesan, seduces and befools Sinuhe, the 
pharaoh’s physician. Sinuhe is bewitched by her charms and sacrifices everything for 
her – even his parents' house and grave – only to be cruelly rejected when Nefer tires 
of playing with him.  
 
The current pandemic of coronavirus disease 2019 (COVID-19) has literally changed 
our lives and the ones of our patients. One year after onset, 61+ million infections have 
been reported resulting in an excess of 1.4 million deaths worldwide,1 and counting. In 
other respiratory virus infections, like influenza, we would expect recovery to pre-
infection quality of life and functionality. However, while many COVID-19 patients 
recover and return to normal health, a yet uncertain proportion of COVID-19 survivors 
persist with lingering, recurrent symptoms for months after recovering from the acute 
condition. These long-term outcomes vary from mild symptoms to severe conditions, 
and sometimes nearly-life threatening episodes. Accordingly, many have not returned 
to their baseline health after weeks, also affecting productivity and emotional status. 
The burden and clinical features of the now called post-COVID-19 syndrome, long-term 
COVID-19, or COVID-19 sequelae, need to be unraveled.  After ICU, the frequency of 
post-intensive care syndrome (PICS) is at the least 50%.2 At ICU discharge, as a result of 
the impact of the acute illness and the hazards of bed rest and hospitalization, nearly 
all survivors of critical illness experience impairments in one or more PICS domains. At 
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3 and 12 months, 64% and 56% of survivors experience one or more new post-
intensive care problems, respectively, and co-occurrence is common.  
 
However, post-COVID-19 syndrome is not a hallmark of critically ill patients, but also 
represents a significant proportion of those that presented with only mild to moderate 
symptoms after the acute infection. One of the first reports (July 9, 2020) on this topic, 
including 143 patients from Italy followed up two months after discharge, identified 
that 87% had at least one persistent symptom, most commonly fatigue and dyspnea; 
and decreased quality of life was observed in 44.1% of the patients in that study.3 Two 
more recent reports produced similar findings: A recent CDC Telephone survey 
conducted April to June 2020 at 14 U.S. academic health care systems in 13 states 
reported that 35% of COVID-19 patients did not return back to their usual health;4 and 
in a Dutch Primary Care series of 126 patients stratified by COVID-19 initial severity, at 
three months follow-up even the 27 mild and 51 moderate patients had symptoms and 
signs in a similar degree than the severe and critical ones.5 In contrast with HIV or 
hepatitis viruses, other coronaviruses usually produce self-limited infections, while 
persistent replication of COVID-19 has only been identified in severely 
immunocompromised patients.6 However, we know that there are significant chronic 
health effects in survivors of community-acquired bacterial pneumonia, including an 
increased risk of heart attack, heart failure, stroke and cognitive impairment.7 As an 
analogy with post-viral pneumonia, in a clinical series of 369 SARS survivors from Hong 
Kong, 42.5% had active psychiatric illnesses and 40.3% reported a chronic fatigue 
problem four years after SARS.8 
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In this issue of the Journal, three European groups report their findings on post-COVID-
19 syndrome in independently collected, prospective, observational cohorts of 
hospitalized COVID-19 patients, who were assessed up to three months past infection 
(Table 1). Namely: Vigeland TV, et al.9 report on symptoms, quality of life, pulmonary 
function, and chest CT findings three months following hospital admission for COVID-
19 in 103 patients from six Norwegian hospitals. Sonnweber T, et al.,10 report on 
similar tests performed in 145 patients from five Austrian centres. And finally, Guler 
SA, et al., 11 report on 113 patients from 13 Swiss centers. In the three studies, COVID-
19 survivors are identified as mild or severe cases based on symptoms/events during 
hospital admission/stay including ICU need, and post-COVID-19 syndrome is 
characterized depending on case severity. Albeit symptoms improve significantly over 
time, about half of these patients present respiratory-related concerns even 4-months 
after discharge, most often dyspnea and impaired lung function. Not surprisingly, the 
more severe patients such as those admitted to an ICU while hospitalized, presented 
the more CT lung abnormalities/pathologies, and reported more trouble in daily-life 
activities. 
 
Strengths of these studies include novelty, tackling an iron-hot medical crisis, quality 
integration of many sites, and use of both routinely/actively collected medical data for 
research purposes, in a situation borderline with near collapse. They have implications 
for clinical research, unravelling the late sequelae, clinical management, public health 
surveillance and health services planning. However, some limitations deserve 
discussion, including: Limited sample size and duration: ranging from 25 to 38 person-
year experience in each of these studies, they add up to a maximum of barely 100 
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person-year altogether; we will need many thousands (millions) of person-year 
experience in COVID-19 survivors to grasp its full scope, and by subgroups, of its 
associated sequalae. Limited statistics: all these studies (but Sonnweber T, et al.,10 with 
two time points) use a pre-post study design, so a continuous assessment with 
generalized linear model (GLM) or other might be also applied. Restricted scope: these 
studies address mostly pulmonary function, yet again Sonnweber T, et al.,10 which also 
collected markers of cardiac function; however, there are increasing reports of chronic 
cardiac,12 and neurological ill-health,13 among other in COVID-19 hospitalized 
survivors, that will certainly contribute to long-term symptoms and functional 
outcomes. Bias: first assessments of any new disease often included selected samples 
carrying common biases such as lead time (information bias), apparent increased 
survival (selection bias), and unmeasured residual confounding, among other biases; 
true representativity will come from population studies from non-elite centers, non-
hospitalized subjects and including patients from low-and-middle-income countries. 
Baseline assessments: understandably, urgency precluded many baseline assessments 
prior to COVID-19, such as the effect of previous smoking exposure or previous lung 
conditions, that have previously resulted in somewhat erroneous interpretations.14 
Applicability of findings: finally, all have insufficient follow-up to know if the observed 
defects are permanent or will resolve; it remains to be seen effects of potential re-
infection, and any eventual immunological effects of different COVID-19 vaccines. In 
addition, no cardiopulmonary exercise testing with oxygen consumption assessment 
was performed to identify muscular impairment.  
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Interestingly, these three studies confirm that in a large proportion of post-COVID 
patients dyspnea and fatigue are not justified by cardiopulmonary tests, as often 
identified in clinical practice. In spite of being hospitalized requiring supplemental 
oxygen, only a small proportion of patients with lung fibrosis, cardiac impairment or 
pulmonary hypertension were indeed identified. Therefore, these findings suggest that 
symptoms alone should not guide the management of long-term COVID-19 patients. 
Moreover, these observations highlight the need to differentiate lung or pulmonary 
vascular (associated with silent micro-thrombosis) injury,15 from (steroids) myopathy 
or the development of a systemic exertion intolerance disease, formerly known as 
chronic fatigue syndrome (SEID/CFS) or myalgic encephalitis. That syndrome was 
characterized by fatigue for longer than 6 months, post-exertional malaise, 
unrefreshing sleep plus orthostatic intolerance or cognitive impairment; pathogenesis 
might be via the immune disbalance associated with SARS-CoV-2 infection, inducing an 
activation in the expression of endogenous viruses or epigenetic changes increasing 
cellular metabolism. 
 
With all likelihood, many more reports pooling patients from either single centers or in 
collaborative national/international efforts,16 will emerge. We have started to collect a 
list of recommendations for future clinical research studies reporting on post-COVID-
19 syndrome (Table 2). Some of them have already been implemented in the 
encompassing three ERJ papers, but the definition itself of what post-COVID-19 
syndrome is, by consensus of the World Health Organization,17 the European Centre 
for Disease Prevention and Control,18 the European Respiratory Society,19 and others, 
or for how long, and which tests to use to assess it, still needs further evidence. 
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Anyway, 4 weeks as breakpoint to identify late sequelae, as proposed by Datta et al.,20 
seems utterly insufficient.  
 
Many unknowns remain on what proportion of COVID-19 survivors will require 
multidisciplinary post-COVID-19 clinics to address both persistent symptoms and 
potential long-term respiratory and other complications (i.e.: acute kidney injury, 
myocarditis, psychiatric outcomes, …).21 And on what standard treatments and 
management strategies should be applied,22 most likely to be periodically revisited 
whenever new, significant evidence be available. It will be another toll of this 
pandemic, to add up to the global risks we face in these most uncertain times.23 
 
These observations have four important clinical implications: 1) the first step is getting 
universal definitions for recovery. Recovery cannot be stated when someone is testing 
negative or being discharged from hospital. A negative follow-up PCR or positive 
antibodies serologic test does not mean recovery neither. The definition should 
include duration, but also severity and fluctuation of symptoms, plus functional status 
and quality of life. It is needed to track people for six-months at the least and set up 
local registers. Second, it is needed to differentiate organ sequelae from SEID/CFS. 
Third, it is needed to identify a biomarker or laboratory test (like we have for acute 
infection or post-acute hyperinflammatory illness). Lastly, it is needed to identify 




Unlike for Sinuhe, no need to repeating three times the name of this disease to 
remember it, as COVID-19 will not be forgotten by patients, their relatives and 
caretakers in the foreseeable future. 
“… Sinuhe, my friend, we have been born into strange times. Everything is melting – 
changing its shape – like clay on a potter’s wheel. Dress is changing, words, customs 
are changing, and people no longer believe in the gods – though they may fear them. 
Sinuhe, my friend, perhaps we were born to see the sunset of the world, for the world 
is already old, and twelve hundred years have passed since the building of the 
pyramids. When I think of this, I want to bury my head in my hands and cry like a 
child.” 









Table 1. Characteristics of each prospective cohort of clinical cases, analysis and main findings on post-COVID-19 respiratory outcomes 
 
 Population Follow up Analysis Main findings 
Vigeland TV, et al.  [9] 103 patients 
across 6 medical 
centers in Norway 
3 months (˜90 
days) after 
admission 
Descriptive analysis of 
patients based on ICU 
admission. Univariate 
logistic model for severity 
indices and respiratory 
outcomes. Multivariate 
logistic model for 
respiratory outcomes 
related to ICU stay. 
Approximately 50% patients presented persistent dyspnoea on 
exertion, and 25% reduced diffusion lung capacity for carbon 
monoxide (DLCO).  
Participants admitted to ICU during hospitalization presented more CT 
abnormalities and reported more problems in daily-life activities, but 
similar lung function and self-reported dyspnoea to those not 
admitted to ICU. 
Sonnweber T, et al. 
[10]  
145 patients 
across 4 medical 
centers in Austria.  
60, and 100 
days after 
admission 
Overall and subgroup 
descriptive analyses for 
time-related differences. 
Secondary analyses using 
adjusted generalized 
linear models to account 
for time-series.  
Major improvement of symptoms over time, however, 41% patients 
presented symptoms after 100 days: most frequently dyspnoea (36%), 
and impaired lung function (21%). Small proportion of patients with 
cardiac impairment or pulmonary hypertension. Frequent finding in CT 
scans of lung pathologies (63%) without fibrosis 
Guler SA, et al. [11]    113 patients 







Descriptive analysis of 
patient’s outcomes 
stratified into mild and 
severe cases. Adjusted 
logistic models for 
radiological features 
related to disease 
severity 
DLCO-percent predicted identified as the single most important factor 
associated with severe/critical COVID-19 translated to reduced 
walking distance and oxygen desaturation on exercise. Presence of 
mosaic hypoattenuation on chest CT at follow-up was significantly 




Table 2. Recommendations for future clinical observational studies on post-COVID-19 
syndrome 
 
1. Reports should follow all/most STROBE recommendations for observational 
research, and attach their checklist 24 
2. Minimal follow-up of six months 
3. Early, active identification of subjects at risk of severe sequelae 
4. Use reference groups (i.e.: hospital controls via electronic health records; or 
population-based controls; or else) 
5. Tests, questionnaires and tools to assess patient outcomes should be pre-
specified as per a protocol 
6. A minimum dataset to merge variables/values/patients in a standard dictionary 
should be implemented  
7. Characterize risk factors known for persistence of symptoms: high blood 
pressure, overweight/obesity, smoking, mental health conditions, other 
comorbidities and their treatment, … 
8. Recording of real-time data with apps, remote sensors and e-health 
9. Assess mental status and post-traumatic stress disorder 
10. Assess quality-of-life of patients (and their carers) objectively 
11. Identify early potential pharmacological (e.g. steroids) and non-pharmacological  
(IMV and NIMV, …) adverse events 
12. Report at the least three sets of serial measurements over time, to fully assess 
recovery 
13. Use objective techniques, like cardiopulmonary exercise test, to assess the 
exercise impairment 
14. Assess effects of targeted rehabilitation 
15. Differentiate from systemic exertion intolerance disease, formerly known as 
chronic fatigue syndrome (SEID/CFS) 
16. Identify laboratory tests or biomarkers to characterize the post-COVID-19 
syndrome 
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